@inbook{3b5eb1cb057f44048a63ed7de7f6a1d9,
title = "Better language through chemistry: Augmenting speech-language therapy with pharmacotherapy in the treatment of aphasia",
abstract = "Speech and language therapy is the standard treatment of aphasia. However, many individuals have barriers in seeking this measure of extensive rehabilitation treatment. Investigating ways to augment therapy is key to improving poststroke language outcomes for all patients with aphasia, and pharmacotherapies provide one such potential solution. Although no medications are currently approved for the treatment of aphasia by the United States Food and Drug Administration, numerous candidate mechanisms for pharmaceutical manipulation continue to be identified based on our evolving understanding of the neurometabolic experience of stroke recovery across molecular, cellular, and functional levels of inquiry. This chapter will review evidence for catecholaminergic, glutamatergic, cholinergic, and serotonergic drug therapies and discuss future directions for both candidate drug selection and pharmacotherapy practice in people with aphasia.",
keywords = "Adjunctive therapy, Amantadine, Donepezil, Levodopa, Memantine, Neural plasticity, Pharmacotherapy, SSRI",
author = "Stockbridge, {Melissa D.}",
note = "Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",
year = "2022",
month = jan,
doi = "10.1016/B978-0-12-823384-9.00013-X",
language = "English (US)",
series = "Handbook of Clinical Neurology",
publisher = "Elsevier B.V.",
pages = "261--272",
booktitle = "Handbook of Clinical Neurology",
}